Stereotactic radiosurgery of early melanoma brain metastases after initiation of anti-CTLA-4 treatment is associated with improved intracranial control.

[1]  K. Patel,et al.  Ipilimumab and Stereotactic Radiosurgery Versus Stereotactic Radiosurgery Alone for Newly Diagnosed Melanoma Brain Metastases , 2017, American journal of clinical oncology.

[2]  H. Tawbi,et al.  Radiation necrosis with stereotactic radiosurgery combined with CTLA-4 blockade and PD-1 inhibition for treatment of intracranial disease in metastatic melanoma , 2017, Journal of Neuro-Oncology.

[3]  B. Stea,et al.  Improved time to disease progression in the brain in patients with melanoma brain metastases treated with concurrent delivery of radiosurgery and ipilimumab , 2017, Oncoimmunology.

[4]  J. Sheehan,et al.  The effect of timing of stereotactic radiosurgery treatment of melanoma brain metastases treated with ipilimumab. , 2017, Journal of neurosurgery.

[5]  A. Grosu,et al.  Immune modulation by hypofractionated stereotactic radiation therapy: Therapeutic implications. , 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[6]  U. Ricardi,et al.  Radiotherapy and immune checkpoints inhibitors for advanced melanoma. , 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[7]  H. Kluger,et al.  Does immunotherapy increase the rate of radiation necrosis after radiosurgical treatment of brain metastases? , 2016, Journal of neurosurgery.

[8]  I. Kaplan,et al.  Ipilmumab and cranial radiation in metastatic melanoma patients: a case series and review , 2015, Journal of Immunotherapy for Cancer.

[9]  C. Parkinson,et al.  Evolving treatment options for melanoma brain metastases. , 2015, The Lancet. Oncology.

[10]  Y. Yamada,et al.  Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment. , 2015, International journal of radiation oncology, biology, physics.

[11]  G. Linette,et al.  Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. , 2015, The New England journal of medicine.

[12]  H. Ishwaran,et al.  Radiation and Dual Checkpoint Blockade Activates Non-Redundant Immune Mechanisms in Cancer , 2015, Nature.

[13]  J. Wolchok,et al.  Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25 , 2015, Cell Research.

[14]  D. Gomez,et al.  Combining Radiation and Immunotherapy: A New Systemic Therapy for Solid Tumors? , 2014, Cancer Immunology Research.

[15]  K. Shirai,et al.  Survival of melanoma patients with brain metastases treated with ipilimumab and stereotactic radiosurgery , 2014, Cancer medicine.

[16]  N. Agarwal,et al.  Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. , 2014, The Lancet. Oncology.

[17]  S. Demaria,et al.  Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death , 2014, Oncoimmunology.

[18]  C. N. Coleman,et al.  Harnessing the Potential of Radiation-Induced Immune Modulation for Cancer Therapy , 2013, Cancer Immunology Research.

[19]  S. Demaria,et al.  An Abscopal Response to Radiation and Ipilimumab in a Patient with Metastatic Non–Small Cell Lung Cancer , 2013, Cancer Immunology Research.

[20]  R. Weichselbaum,et al.  Radiation as an immune modulator. , 2013, Seminars in radiation oncology.

[21]  N. Popitsch,et al.  CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients , 2013, Clinical Cancer Research.

[22]  Annie Bruns,et al.  Radiation‐induced loss of cell surface CD47 enhances immune‐mediated clearance of human papillomavirus‐positive cancer , 2013, International journal of cancer.

[23]  L. Zitvogel,et al.  Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  K. Öberg.  Implications for Clinical Practice and Trial Design , 2012 .

[25]  A. Hoos.  Evolution of end points for cancer immunotherapy trials. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  J. Knisely,et al.  Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. , 2012, Journal of neurosurgery.

[27]  M. Shah,et al.  A Man with Klinefelter’s Syndrome and New Abdominal Distension: A Discussion of Evaluation and Management , 2012, Journal of Gastrointestinal Cancer.

[28]  S. Knox,et al.  Abscopal effect in a patient with melanoma. , 2012, The New England journal of medicine.

[29]  J. Wolchok,et al.  Evaluation of the absolute lymphocyte count as a biomarker for melanoma patients treated with the commercially available dose of ipilimumab (3mg/kg). , 2012 .

[30]  N. Mounier,et al.  Secondary surgery with intraoperative chemohyperthermia in recurrent ovarian adenocarcinoma. , 2012 .

[31]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[32]  Jedd D. Wolchok,et al.  Immunologic correlates of the abscopal effect in a patient with melanoma. , 2012, The New England journal of medicine.

[33]  George Coukos,et al.  Cancer immunotherapy comes of age , 2011, Nature.

[34]  Axel Hoos,et al.  Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. , 2011, The New England journal of medicine.

[35]  Donna Neuberg,et al.  Active immunotherapy induces antibody responses that target tumor angiogenesis. , 2010, Cancer research.

[36]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[37]  J. Wolchok,et al.  Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting , 2010, Cancer.

[38]  K. Hess,et al.  Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. , 2009, The Lancet. Oncology.

[39]  A. Scorilas,et al.  Prognostic value of kallikrein‐related peptidase 6 protein expression levels in advanced ovarian cancer evaluated by automated quantitative analysis (AQUA) , 2008, Cancer science.

[40]  B. Czerniecki,et al.  Radiation therapy and Toll-like receptor signaling: implications for the treatment of cancer , 2008, Oncogene.

[41]  Hiroki Shirato,et al.  Stereotactic Radiosurgery Plus Whole-Brain Radiation Therapy vs Stereotactic Radiosurgery Alone for Treatment of Brain Metastases: A Randomized Controlled Trial , 2007 .

[42]  G. Freeman,et al.  Tissue expression of PD-L1 mediates peripheral T cell tolerance , 2006, The Journal of experimental medicine.

[43]  N. Kawashima,et al.  Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[44]  D. Rimm,et al.  X-Tile , 2004, Clinical Cancer Research.

[45]  R. Schreiber,et al.  Cancer immunoediting: from immunosurveillance to tumor escape , 2002, Nature Immunology.

[46]  D. Sansom,et al.  CD28, CTLA‐4 and their ligands: who does what and to whom? , 2000, Immunology.

[47]  L Souhami,et al.  Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05. , 2000, International journal of radiation oncology, biology, physics.

[48]  C. June,et al.  CTLA-4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis. , 1996, Journal of immunology.

[49]  R. Jain,et al.  Effect of radiation on interstitial fluid pressure and oxygenation in a human tumor xenograft. , 1996, Cancer research.

[50]  W. Sauerbrei,et al.  Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. , 1994, Journal of the National Cancer Institute.

[51]  Y. Yamada,et al.  Ipilimumab and whole brain radiation therapy for melanoma brain metastases , 2014, Journal of Neuro-Oncology.